methadone has been researched along with Pain, Chronic in 91 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways." | 9.41 | Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature. ( Mercadante, S, 2023) |
| "Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse." | 9.41 | A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being. ( Cooperman, NA; Garland, EL; Hanley, AW; Kline, A, 2021) |
| "The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study." | 9.27 | Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes. ( Cryer, B; Drossman, DA; Losch-Beridon, T; Mareya, SM; Mazen Jamal, M; Spierings, ELH; Wang, M, 2018) |
| "Opioids increase the risk for sleep disordered breathing (SDB), but there are few studies examining the prevalence and risk factors for SDB, specifically central sleep apnea (CSA), and obstructive sleep apnea (OSA) in chronic pain patients on opioids as well as methadone maintained patients (MMPs)." | 8.93 | A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. ( Hassamal, S; Miotto, K; Saxon, AJ; Wang, T, 2016) |
| "This systematic review synthesizes the evidence related to methadone use and risk for overdose and cardiac arrhythmia." | 8.90 | Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. ( Chou, R; Dana, T; Weimer, MB, 2014) |
| "Many individuals receiving methadone maintenance treatment (MMT) for opioid addiction also require treatment for acute or chronic pain, and the presence of pain is known to have a negative impact on patient health and function." | 8.89 | Chronic and acute pain and pain management for patients in methadone maintenance treatment. ( Eyler, EC, 2013) |
| "This study examined the cross-sectional associations among pain intensity, pain catastrophizing, and sleep disturbance among patients receiving methadone maintenance treatment (MMT) for opioid use disorder (OUD) and reporting co-occurring chronic pain." | 7.96 | Associations Among Sleep Disturbance, Pain Catastrophizing, and Pain Intensity for Methadone-maintained Patients With Opioid Use Disorder and Chronic Pain. ( Barry, DT; Beitel, M; Edwards, KA; Eller, A; Ponce Martinez, C; Roos, CR, 2020) |
| " Addressing these barriers in drug counselor training and in methadone maintenance treatment programs may benefit both methadone-maintained patients with chronic pain and their providers." | 7.85 | Drug Counselor Responses to Patients' Pain Reports: A Qualitative Investigation of Barriers and Facilitators to Treating Patients with Chronic Pain in Methadone Maintenance Treatment. ( Barry, DT; Beitel, M; Ginn, J; Kahn, M; Kerns, RD; Liong, C; Madden, LM; Oberleitner, L, 2017) |
| "Physical activity may improve chronic pain, anxiety, and depression, which are prevalent among patients in methadone maintenance treatment (MMT), but relatively little is known about the physical activity levels or interest in exercise of patients in MMT." | 7.83 | Physical activity, psychiatric distress, and interest in exercise group participation among individuals seeking methadone maintenance treatment with and without chronic pain. ( Barry, DT; Beitel, M; Cutter, CJ; Eggert, K; Ginn, J; Kerns, RD; Liong, C; Madden, LM; Schottenfeld, RS; Stults-Kolehmainen, M, 2016) |
| "How to taper and discontinue methadone therapy for chronic pain management is illustrated through a case report." | 7.81 | Tapering and discontinuation of methadone for chronic pain. ( Breivik, H, 2015) |
| "Urine samples from 921 patients prescribed opioids for chronic pain were analyzed for promethazine." | 7.81 | Promethazine use among chronic pain patients. ( Coffa, D; Kral, AH; Lynch, KL; Novak, SP; Shapiro, BJ, 2015) |
| "We conducted a prospective cohort study in a chronic pain clinic including 82 patients receiving methadone and 102 patients receiving non-methadone opioid therapy." | 7.81 | The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. ( Ashburn, MA; Edson, E; Farrar, JT; Grodofsky, S; Hatchimonji, J; Huang, S; Lacy, K; Speck, RM, 2015) |
| "Patients with opioid use disorder maintained on methadone report more chronic pain than the general population." | 7.80 | Severity and interference of chronic pain in methadone-maintained outpatients. ( Brooner, RK; Clark, MR; Dunn, KE, 2014) |
| "Methadone, used both to treat opioid addiction and to manage chronic pain, is commonly prescribed as an opioid of choice for patients with chronic pain and comorbid substance use disorders." | 7.78 | Methadone in the chronic pain patient with a substance use disorder. ( Friedman, CK; Reisfield, GM, 2012) |
| " Participants receive inpatient rotation to either BuNa or methadone with a flexible dosing regimen." | 7.11 | Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. ( Dahan, A; Ellerbroek, H; Kramers, C; Schellekens, AFA; Timmerman, H; van den Heuvel, SAS, 2022) |
| "Our primary objective was test the hypothesis that oral methadone combined with oral ketamine is more effective than oral methadone or ketamine alone in reducing neuropathic pain." | 6.84 | Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial. ( Caumo, W; Dalmolin, GD; Ferreira, J; Godoy, MC; Menezes, MS; Rigo, FK; Rossato, MF; Silva, MA; Trevisan, G, 2017) |
| "Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone." | 6.78 | A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. ( Azadfard, M; Blondell, RD; Giambrone, AK; Homish, GG; Jaanimägi, U; Kowalik, U; Lozano, JR; Neumann, AM, 2013) |
| "To assess studies examining the prevalence of chronic pain (CP) in patients treated with Opioid Substitution Treatment (OST - buprenorphine or methadone) for Opioid Used Disorder (OUD), we conducted a systematic review and meta-analysis of the literature between the years 2000 and 2020." | 5.41 | Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy. ( Authier, N; Bertin, C; Chenaf, C; Delorme, J; Kerckhove, N; Pereira, B, 2023) |
| "Intravenous methadone may be useful in acute and chronic pain management compared with other opioids because of its pharmacokinetic and pharmacodynamic characteristics, including the long duration of effect and ability to modulate both pain stimuli propagation and analgesic descending pathways." | 5.41 | Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature. ( Mercadante, S, 2023) |
| "Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse." | 5.41 | A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being. ( Cooperman, NA; Garland, EL; Hanley, AW; Kline, A, 2021) |
| "Methadone and EDDP were quantified by liquid chromatography-tandem mass spectrometry." | 5.38 | Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients. ( Atayee, RS; Best, BM; Leimanis, E; Pesce, AJ, 2012) |
| "The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study." | 5.27 | Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes. ( Cryer, B; Drossman, DA; Losch-Beridon, T; Mareya, SM; Mazen Jamal, M; Spierings, ELH; Wang, M, 2018) |
| " Methadone is a medication-assisted treatment used to treat opioid dependence and chronic pain." | 5.05 | The effect of methadone on the hypothalamic pituitary gonadal axis and sexual function: A systematic review. ( Ortman, HA; Siegel, JA, 2020) |
| "Methadone has unique characteristics that make it an attractive agent for the treatment of chronic pain and opioid drug dependence." | 5.05 | Levorphanol versus methadone use: safety considerations. ( Haider, A; Reddy, A, 2020) |
| "Opioids increase the risk for sleep disordered breathing (SDB), but there are few studies examining the prevalence and risk factors for SDB, specifically central sleep apnea (CSA), and obstructive sleep apnea (OSA) in chronic pain patients on opioids as well as methadone maintained patients (MMPs)." | 4.93 | A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. ( Hassamal, S; Miotto, K; Saxon, AJ; Wang, T, 2016) |
| "While chronic pain has been said to impact patient's response to methadone maintenance treatment for opioid dependence, the reported findings are inconsistent." | 4.93 | Pain and Opioid Addiction: A Systematic Review and Evaluation of Pain Measurement in Patients with Opioid Dependence on Methadone Maintenance Treatment. ( Bawor, M; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Pare, G; Paul, J; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A, 2016) |
| "This systematic review synthesizes the evidence related to methadone use and risk for overdose and cardiac arrhythmia." | 4.90 | Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. ( Chou, R; Dana, T; Weimer, MB, 2014) |
| "Many individuals receiving methadone maintenance treatment (MMT) for opioid addiction also require treatment for acute or chronic pain, and the presence of pain is known to have a negative impact on patient health and function." | 4.89 | Chronic and acute pain and pain management for patients in methadone maintenance treatment. ( Eyler, EC, 2013) |
| "We identified both randomized controlled trials (RCTs) and non-randomized studies of methadone use in chronic pain by searching the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2011, issue 11, MEDLINE (1950 to November 2011), and EMBASE (1980 to November 2011), together with reference lists of retrieved papers and reviews." | 4.88 | Methadone for chronic non-cancer pain in adults. ( Haroutiunian, S; Lipman, AG; McNicol, ED, 2012) |
| "Over half reported chronic pain, and rates were highest among women and patients receiving methadone." | 4.02 | Chronic Pain Among Patients With an Opioid Use Disorder. ( Latif, ZH; Skjaervø, I; Solli, KK; Tanum, L, 2021) |
| "This study examined the cross-sectional associations among pain intensity, pain catastrophizing, and sleep disturbance among patients receiving methadone maintenance treatment (MMT) for opioid use disorder (OUD) and reporting co-occurring chronic pain." | 3.96 | Associations Among Sleep Disturbance, Pain Catastrophizing, and Pain Intensity for Methadone-maintained Patients With Opioid Use Disorder and Chronic Pain. ( Barry, DT; Beitel, M; Edwards, KA; Eller, A; Ponce Martinez, C; Roos, CR, 2020) |
| "We recruited 109 participants: (i) patients with a history of opioid dependence due to chronic heroin use (n = 24), (ii) heroin users stabilised on methadone maintenance treatment (n = 29), (iii) participants with a history of chronic pain and prescribed tramadol and codeine (n = 28) and (iv) healthy controls (n = 28)." | 3.91 | Profiles of visuospatial memory dysfunction in opioid-exposed and dependent populations. ( Baldacchino, A; Balfour, DJ; Matthews, K; Tolomeo, S, 2019) |
| "Opioid use disorder, chronic pain relief, methadone maintenance treatment, prescriptions, male, female." | 3.88 | Association Between Socio-Demographic and Health Functioning Variables Among Patients with Opioid Use Disorder Introduced by Prescription: A Prospective Cohort Study. ( Bhatt, M; de Souza, R; Luo, C; Samaan, MC; Samaan, Z; Sanger, N; Shahid, H; Shams, I; Tam, SL; Thabane, L, 2018) |
| "Methadone is effective for the treatment of chronic pain, but its unique pharmacology requires additional considerations with dosing and monitoring." | 3.85 | Methadone Inpatient and Discharge Prescribing Patterns for Pain at an Academic Health System. ( Atayee, RS; Edmonds, KP; Hollenbach, KA; Hur, GH; Karimian, P, 2017) |
| " Addressing these barriers in drug counselor training and in methadone maintenance treatment programs may benefit both methadone-maintained patients with chronic pain and their providers." | 3.85 | Drug Counselor Responses to Patients' Pain Reports: A Qualitative Investigation of Barriers and Facilitators to Treating Patients with Chronic Pain in Methadone Maintenance Treatment. ( Barry, DT; Beitel, M; Ginn, J; Kahn, M; Kerns, RD; Liong, C; Madden, LM; Oberleitner, L, 2017) |
| "Chronic pain is implicated as a risk factor for illicit opioid use among patients with opioid addiction treated with methadone." | 3.83 | Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment. ( Bawor, M; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Pare, G; Paul, J; Plater, C; Roshanov, PS; Samaan, Z; Thabane, L; Varenbut, M; Worster, A, 2016) |
| " The objective of this study was to identify risk factors and determine awareness of risk for opioid overdose in veterans treated with opioids for chronic pain, using veterans treated with methadone or buprenorphine for opioid use disorder as a high-risk comparator group." | 3.83 | Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. ( Miller, SC; Stein, MD; Tiffany, E; Wilder, CM; Winhusen, T; Winstanley, EL, 2016) |
| "Physical activity may improve chronic pain, anxiety, and depression, which are prevalent among patients in methadone maintenance treatment (MMT), but relatively little is known about the physical activity levels or interest in exercise of patients in MMT." | 3.83 | Physical activity, psychiatric distress, and interest in exercise group participation among individuals seeking methadone maintenance treatment with and without chronic pain. ( Barry, DT; Beitel, M; Cutter, CJ; Eggert, K; Ginn, J; Kerns, RD; Liong, C; Madden, LM; Schottenfeld, RS; Stults-Kolehmainen, M, 2016) |
| "How to taper and discontinue methadone therapy for chronic pain management is illustrated through a case report." | 3.81 | Tapering and discontinuation of methadone for chronic pain. ( Breivik, H, 2015) |
| "Little is known about the experience of chronic pain and the occurrence of illicit drug use behaviors in the population enrolled in methadone maintenance treatment (MMT) programs." | 3.81 | Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance. ( Cheatle, MD; Chen, J; Dhingra, L; Jordan, AE; Masson, C; McKnight, C; Perlman, DC; Portenoy, RK; Wasser, T, 2015) |
| "We conducted a prospective cohort study in a chronic pain clinic including 82 patients receiving methadone and 102 patients receiving non-methadone opioid therapy." | 3.81 | The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. ( Ashburn, MA; Edson, E; Farrar, JT; Grodofsky, S; Hatchimonji, J; Huang, S; Lacy, K; Speck, RM, 2015) |
| "Urine samples from 921 patients prescribed opioids for chronic pain were analyzed for promethazine." | 3.81 | Promethazine use among chronic pain patients. ( Coffa, D; Kral, AH; Lynch, KL; Novak, SP; Shapiro, BJ, 2015) |
| "The aim of this qualitative study was to examine the narratives of people who experience chronic pain (lasting 6 months or more) and were receiving methadone for the treatment of their opiate addiction through a major methadone clinic." | 3.80 | Coexisting addiction and pain in people receiving methadone for addiction. ( St Marie, B, 2014) |
| "Patients with opioid use disorder maintained on methadone report more chronic pain than the general population." | 3.80 | Severity and interference of chronic pain in methadone-maintained outpatients. ( Brooner, RK; Clark, MR; Dunn, KE, 2014) |
| "Surveys of current trends indicate heroin abuse is associated with nonmedical use of pain relievers." | 3.80 | Prevalence of heroin markers in urine for pain management patients. ( Black, DL; Caplan, YH; Cone, EJ; DePriest, A; Heltsley, R; Hild, C; Knight, J; Puet, BL; Robert, T, 2014) |
| " Conversely, oral oxycodone and methadone were ineffective in controlling chronic pain despite high doses and aggressive titration." | 3.78 | Unpredictable absorption of oral opioid medications in a quadriplegic patient with chronic enterocutaneous fistulas. ( Viswesh, VV, 2012) |
| "Methadone, used both to treat opioid addiction and to manage chronic pain, is commonly prescribed as an opioid of choice for patients with chronic pain and comorbid substance use disorders." | 3.78 | Methadone in the chronic pain patient with a substance use disorder. ( Friedman, CK; Reisfield, GM, 2012) |
| " Using an attentional bias (AB) task with both pain and opioid cues, we evaluated a cognitive bias modification (CBM) task administered during regularly scheduled medications for OUD (mOUD) dosing visits." | 3.30 | Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. ( Heapy, AA; MacLean, RR; Meyerovich, J; Sofuoglu, M; Szollosy, SK; Waters, AJ; Wolkowicz, N, 2023) |
| " Participants receive inpatient rotation to either BuNa or methadone with a flexible dosing regimen." | 3.11 | Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. ( Dahan, A; Ellerbroek, H; Kramers, C; Schellekens, AFA; Timmerman, H; van den Heuvel, SAS, 2022) |
| "The coexistence of opioid use disorder (OUD) in patients with chronic pain represents a complex challenge due to the need for managing both pain and OUD." | 3.01 | Systematic review on the clinical management of chronic pain and comorbid opioid use disorder. ( Calomarde-Gómez, C; Gual, A; Jiménez-Fernández, B; Lligoña, A; López-Lazcano, A; López-Pelayo, H, 2023) |
| "Participants with OUD and chronic pain (N = 30) were randomized to 8 weeks of MORE or treatment as usual (TAU)." | 2.90 | Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial. ( Cooperman, NA; Garland, EL; Hanley, AW; Kline, A, 2019) |
| "Our primary objective was test the hypothesis that oral methadone combined with oral ketamine is more effective than oral methadone or ketamine alone in reducing neuropathic pain." | 2.84 | Management of Neuropathic Chronic Pain with Methadone Combined with Ketamine: A Randomized, Double Blind, Active-Controlled Clinical Trial. ( Caumo, W; Dalmolin, GD; Ferreira, J; Godoy, MC; Menezes, MS; Rigo, FK; Rossato, MF; Silva, MA; Trevisan, G, 2017) |
| "Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone." | 2.78 | A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. ( Azadfard, M; Blondell, RD; Giambrone, AK; Homish, GG; Jaanimägi, U; Kowalik, U; Lozano, JR; Neumann, AM, 2013) |
| "Methadone has a unique mechanism of action when compared with all other opioids and for this reason methadone has come to hold a niche role in the management of opioid-induced hyperalgesia and central sensitization." | 2.66 | Methadone for Pain Management: A Pharmacotherapeutic Review. ( Kreutzwiser, D; Tawfic, QA, 2020) |
| "Chronic pain affects millions of adults in the USA." | 2.61 | Comprehensive Perioperative Management Considerations in Patients Taking Methadone. ( Anyama, BC; Cornett, EM; Gennuso, SA; Green, JB; Kaye, AD; Kline, RJ; Okereke, EC; Robichaux, SL, 2019) |
| "The use of opioids to treat chronic pain has come under increased scrutiny, as such use has been associated with significant risk of death, with limited data regarding the long-term effectiveness, especially when used to treat noncancer pain." | 2.52 | Cardiac Effects of Opioid Therapy. ( Ashburn, MA; Chen, A, 2015) |
| " There was credible evidence of a strong relationship between opioids and SDB with noted risk factors including use of methadone, high opioid dosing (>200 mg MED) and combining opioids with benzodiazepines." | 2.52 | Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. ( Cheatle, MD; Webster, LR, 2015) |
| " There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians." | 1.72 | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life. ( Albury, CL; George, R; Good, P; Griffiths, LR; Hardy, J; Haupt, LM; Haywood, A; Ozberk, D; Sutherland, HG; Yu, C; Zunk, M, 2022) |
| "Patients with PTSD had higher proportion of chronic pain and high-perceived stress, and lower pain threshold, with similar supra-threshold ratings." | 1.62 | Post-traumatic stress disorder due to sexual abuse and its relation to pain sensitivity among patients in methadone maintenance treatment. ( Adelson, M; Lamhoot, T; Peles, E; Sason, A; Schreiber, S, 2021) |
| "The independent variable was chronic pain measured at study inception using the Brief Pain Inventory-Short Form." | 1.56 | Comparison of psychiatric comorbidity in treatment-seeking, opioid-dependent patients with versus without chronic pain. ( Higgins, C; Matthews, K; Smith, BH, 2020) |
| "Pharmacological management of neuropathic pain should be based on a stepwise intervention strategy, as combinations of medications are the most effective approach." | 1.51 | Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm. ( Anghelescu, DL; Tesney, JM, 2019) |
| "We compared the risk of serious infection among patients initiating long-acting opioid analgesics with and without previously reported immunosuppressive properties." | 1.51 | Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study. ( Greevy, RA; Griffin, MR; Grijalva, CG; Mitchel, EF; Schaffner, W; Stein, CM; Wiese, AD, 2019) |
| "Despite high rates of chronic pain among their patients, opioid agonist treatment (OAT) counselors report an absence of training to manage chronic pain." | 1.48 | Training addiction counselors to deliver a brief psychoeducational intervention for chronic pain among patients in opioid agonist treatment: A pilot investigation. ( Barry, DT; Beitel, M; Bone, C; Bono, MH; Butner, JL; Eller, A; Kwon, G; Madden, LM; Ponce Martinez, CC, 2018) |
| "Compared with nociceptive pain, neuropathic pain is a challenging diagnosis to make and successfully treat in children with cancer." | 1.46 | Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer. ( Bruera, E; Madden, K, 2017) |
| "Chronic pain was present in 68% of the sample, 51% reported craving opioids in the past week, and 16% had a positive UDT." | 1.43 | Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Samet, JH; Tsui, JI; Winter, MR, 2016) |
| "Chronic pain is common among patients receiving opioid maintenance treatment (OMT) for opioid use disorder." | 1.42 | Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. ( Dunn, KE; Finan, PH; Fingerhood, M; Strain, EC; Tompkins, DA, 2015) |
| "Methadone maintenance treatment (MMT) patients may achieve up to a 2-week privilege of methadone take-home doses (THD), which is associated with considerable responsibility." | 1.40 | Achievement of take-home dose privileges is associated with better-perceived sleep and with cognitive status among methadone maintenance treatment patients. ( Adelson, M; Domany, Y; Peles, E; Sason, A; Schreiber, S; Tene, O, 2014) |
| " Eighty per cent of patients were not asked about their ability to swallow solid, oral dosage forms by their physician." | 1.40 | Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. ( Carlson, DR; Kopecky, EA; Nalamachu, S; Pergolizzi, JV; Raffa, RB; Taylor, R; Varanasi, RK, 2014) |
| "Methadone and EDDP were quantified by liquid chromatography-tandem mass spectrometry." | 1.38 | Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients. ( Atayee, RS; Best, BM; Leimanis, E; Pesce, AJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.10) | 29.6817 |
| 2010's | 67 (73.63) | 24.3611 |
| 2020's | 23 (25.27) | 2.80 |
| Authors | Studies |
|---|---|
| Gaeta Gazzola, M | 1 |
| Carmichael, ID | 1 |
| Madden, LM | 5 |
| Dasgupta, N | 1 |
| Beitel, M | 8 |
| Zheng, X | 1 |
| Eggert, KF | 1 |
| Farnum, SO | 1 |
| Barry, DT | 8 |
| Jasmine Silva, M | 1 |
| Coffee, Z | 1 |
| Goza, J | 1 |
| Rumrill, K | 1 |
| Jiménez-Fernández, B | 1 |
| Calomarde-Gómez, C | 1 |
| López-Lazcano, A | 1 |
| Lligoña, A | 1 |
| Gual, A | 1 |
| López-Pelayo, H | 1 |
| Ellerbroek, H | 1 |
| van den Heuvel, SAS | 1 |
| Dahan, A | 1 |
| Timmerman, H | 1 |
| Kramers, C | 1 |
| Schellekens, AFA | 1 |
| Delorme, J | 1 |
| Kerckhove, N | 1 |
| Authier, N | 1 |
| Pereira, B | 1 |
| Bertin, C | 1 |
| Chenaf, C | 1 |
| Ozberk, D | 1 |
| Haywood, A | 1 |
| Sutherland, HG | 1 |
| Yu, C | 1 |
| Albury, CL | 1 |
| Zunk, M | 1 |
| George, R | 1 |
| Good, P | 1 |
| Griffiths, LR | 1 |
| Hardy, J | 1 |
| Haupt, LM | 1 |
| MacLean, RR | 1 |
| Heapy, AA | 1 |
| Waters, AJ | 1 |
| Wolkowicz, N | 1 |
| Szollosy, SK | 1 |
| Meyerovich, J | 1 |
| Sofuoglu, M | 1 |
| Mercadante, S | 1 |
| Garland, EL | 2 |
| Hanley, AW | 2 |
| Kline, A | 2 |
| Cooperman, NA | 2 |
| Uebelacker, LA | 1 |
| Van Noppen, D | 1 |
| Tremont, G | 1 |
| Bailey, G | 1 |
| Abrantes, A | 1 |
| Stein, M | 1 |
| Roxburgh, A | 1 |
| Hall, WD | 1 |
| Gisev, N | 1 |
| Degenhardt, L | 1 |
| Rosen, KD | 1 |
| Curtis, ME | 1 |
| Potter, JS | 1 |
| Ortman, HA | 1 |
| Siegel, JA | 1 |
| Haider, A | 1 |
| Reddy, A | 1 |
| Ponce Martinez, C | 1 |
| Edwards, KA | 1 |
| Roos, CR | 1 |
| Eller, A | 2 |
| Kreutzwiser, D | 1 |
| Tawfic, QA | 1 |
| Avram, MJ | 1 |
| Murphy, GS | 1 |
| Szokol, JW | 1 |
| Romanoff, M | 1 |
| Rajput, K | 1 |
| Vadivelu, N | 1 |
| Lamhoot, T | 1 |
| Adelson, M | 3 |
| Sason, A | 3 |
| Schreiber, S | 3 |
| Peles, E | 3 |
| Benville, JR | 1 |
| Compton, P | 1 |
| Giordano, NA | 1 |
| Cheatle, MD | 3 |
| Butler, SH | 1 |
| Latif, ZH | 1 |
| Skjaervø, I | 1 |
| Solli, KK | 1 |
| Tanum, L | 1 |
| Sohn, M | 1 |
| Talbert, JC | 1 |
| Huang, Z | 1 |
| Oser, C | 1 |
| Freeman, PR | 1 |
| Rigo, FK | 2 |
| Trevisan, G | 1 |
| Godoy, MC | 1 |
| Rossato, MF | 2 |
| Dalmolin, GD | 2 |
| Silva, MA | 1 |
| Menezes, MS | 1 |
| Caumo, W | 1 |
| Ferreira, J | 2 |
| Madden, K | 1 |
| Bruera, E | 1 |
| Zhou, K | 1 |
| Jia, P | 1 |
| Bhargava, S | 1 |
| Zhang, Y | 1 |
| Reza, T | 1 |
| Peng, YB | 1 |
| Wang, GG | 1 |
| Spierings, ELH | 1 |
| Drossman, DA | 1 |
| Cryer, B | 1 |
| Mazen Jamal, M | 1 |
| Losch-Beridon, T | 1 |
| Mareya, SM | 1 |
| Wang, M | 1 |
| Masharani, U | 1 |
| Alba, D | 1 |
| Aiyer, R | 1 |
| Gulati, A | 1 |
| Gungor, S | 1 |
| Bhatia, A | 1 |
| Mehta, N | 1 |
| Mordecai, L | 1 |
| Reynolds, C | 1 |
| Donaldson, LJ | 1 |
| de C Williams, AC | 1 |
| Larsen, IM | 1 |
| Drewes, AM | 1 |
| Olesen, AE | 1 |
| Butner, JL | 1 |
| Bone, C | 1 |
| Ponce Martinez, CC | 1 |
| Kwon, G | 1 |
| Bono, MH | 1 |
| LeBlanc, Z | 1 |
| Vance, C | 1 |
| Payne, J | 1 |
| Zhang, J | 1 |
| Hilliard, L | 1 |
| Lebensburger, JD | 1 |
| Howard, TH | 1 |
| Wiese, AD | 1 |
| Griffin, MR | 1 |
| Schaffner, W | 1 |
| Stein, CM | 2 |
| Greevy, RA | 1 |
| Mitchel, EF | 1 |
| Grijalva, CG | 1 |
| Higgins, C | 2 |
| Smith, BH | 2 |
| Matthews, K | 3 |
| Baldacchino, A | 1 |
| Tolomeo, S | 1 |
| Balfour, DJ | 1 |
| Cutter, CJ | 4 |
| Fiellin, DA | 1 |
| Kerns, RD | 4 |
| Moore, BA | 1 |
| Oberleitner, L | 2 |
| Liong, C | 4 |
| Ginn, J | 3 |
| Schottenfeld, RS | 3 |
| Sanger, N | 1 |
| Bhatt, M | 1 |
| Shams, I | 1 |
| Shahid, H | 1 |
| Luo, C | 1 |
| Tam, SL | 1 |
| Samaan, MC | 1 |
| de Souza, R | 1 |
| Thabane, L | 3 |
| Samaan, Z | 3 |
| Humphreys, K | 1 |
| Saitz, R | 1 |
| Anghelescu, DL | 1 |
| Tesney, JM | 1 |
| Babu, KM | 1 |
| Brent, J | 1 |
| Juurlink, DN | 1 |
| Cornett, EM | 1 |
| Kline, RJ | 1 |
| Robichaux, SL | 1 |
| Green, JB | 1 |
| Anyama, BC | 1 |
| Gennuso, SA | 1 |
| Okereke, EC | 1 |
| Kaye, AD | 1 |
| Wachholtz, A | 1 |
| Gonzalez, G | 1 |
| Ziedonis, D | 1 |
| Pilgrim, JL | 1 |
| McDonough, M | 1 |
| Drummer, OH | 1 |
| Neumann, AM | 1 |
| Blondell, RD | 1 |
| Jaanimägi, U | 1 |
| Giambrone, AK | 1 |
| Homish, GG | 1 |
| Lozano, JR | 1 |
| Kowalik, U | 1 |
| Azadfard, M | 1 |
| de Godoy, MC | 1 |
| de Menezes, MS | 1 |
| Alvarez, MA | 1 |
| Hernandes, JJ | 1 |
| Moreno, LA | 1 |
| Sinche, M | 1 |
| Keane, H | 1 |
| Savant, JD | 1 |
| Peters, S | 1 |
| Belisle, N | 1 |
| Webster, LR | 2 |
| St Marie, B | 1 |
| Pergolizzi, JV | 1 |
| Taylor, R | 1 |
| Nalamachu, S | 1 |
| Raffa, RB | 1 |
| Carlson, DR | 1 |
| Varanasi, RK | 1 |
| Kopecky, EA | 1 |
| Luk, S | 1 |
| Atayee, RS | 3 |
| Ma, JD | 1 |
| Best, BM | 2 |
| Domany, Y | 2 |
| Tene, O | 2 |
| Chou, R | 1 |
| Weimer, MB | 1 |
| Dana, T | 1 |
| Dunn, KE | 2 |
| Brooner, RK | 1 |
| Clark, MR | 1 |
| Knight, J | 1 |
| Puet, BL | 1 |
| DePriest, A | 1 |
| Heltsley, R | 1 |
| Hild, C | 1 |
| Black, DL | 1 |
| Robert, T | 1 |
| Caplan, YH | 1 |
| Cone, EJ | 1 |
| Hendrikson, H | 1 |
| Hansen, M | 1 |
| Grodofsky, S | 1 |
| Edson, E | 1 |
| Huang, S | 1 |
| Speck, RM | 1 |
| Hatchimonji, J | 1 |
| Lacy, K | 1 |
| Farrar, JT | 1 |
| Ashburn, MA | 2 |
| Dhingra, L | 1 |
| Perlman, DC | 1 |
| Masson, C | 1 |
| Chen, J | 1 |
| McKnight, C | 1 |
| Jordan, AE | 1 |
| Wasser, T | 1 |
| Portenoy, RK | 1 |
| Lynch, KL | 1 |
| Shapiro, BJ | 1 |
| Coffa, D | 1 |
| Novak, SP | 1 |
| Kral, AH | 1 |
| Stevenson, E | 1 |
| Cole, J | 1 |
| Breivik, H | 1 |
| Voon, P | 1 |
| Hayashi, K | 1 |
| Milloy, MJ | 1 |
| Nguyen, P | 1 |
| Wood, E | 1 |
| Montaner, J | 1 |
| Kerr, T | 1 |
| Chen, A | 1 |
| Finan, PH | 1 |
| Tompkins, DA | 1 |
| Fingerhood, M | 1 |
| Strain, EC | 1 |
| Wilder, CM | 1 |
| Miller, SC | 1 |
| Tiffany, E | 1 |
| Winhusen, T | 1 |
| Winstanley, EL | 1 |
| Stein, MD | 1 |
| Dennis, BB | 2 |
| Roshanov, PS | 1 |
| Bawor, M | 2 |
| Paul, J | 2 |
| Varenbut, M | 2 |
| Daiter, J | 2 |
| Plater, C | 2 |
| Pare, G | 2 |
| Marsh, DC | 2 |
| Worster, A | 2 |
| Desai, D | 2 |
| Stults-Kolehmainen, M | 1 |
| Eggert, K | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Murray, KT | 1 |
| Hall, K | 1 |
| Tsui, JI | 1 |
| Lira, MC | 1 |
| Cheng, DM | 1 |
| Winter, MR | 1 |
| Alford, DP | 1 |
| Liebschutz, JM | 1 |
| Edwards, RR | 1 |
| Samet, JH | 1 |
| Bertholf, RL | 1 |
| Sharma, R | 1 |
| Reisfield, GM | 2 |
| Hassamal, S | 1 |
| Miotto, K | 1 |
| Wang, T | 1 |
| Saxon, AJ | 1 |
| Hur, GH | 1 |
| Karimian, P | 1 |
| Hollenbach, KA | 1 |
| Edmonds, KP | 1 |
| Kahn, M | 1 |
| Farahmand, N | 1 |
| Drennan, D | 1 |
| Junkins, S | 1 |
| Rastogi, R | 1 |
| Swarm, RA | 1 |
| Patel, TA | 1 |
| Calver, L | 1 |
| Dunlop, AJ | 1 |
| Isbister, GK | 1 |
| Leimanis, E | 1 |
| Pesce, AJ | 1 |
| Collins, AA | 1 |
| Merritt, AP | 1 |
| Bourland, JA | 1 |
| Viswesh, VV | 1 |
| Haroutiunian, S | 1 |
| McNicol, ED | 1 |
| Lipman, AG | 1 |
| Friedman, CK | 1 |
| Green, JS | 1 |
| Dillane, D | 1 |
| Tsui, BC | 1 |
| Eyler, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Behavioral Intervention to Improve Insomnia Symptoms in Patients With Opioid Use Disorder[NCT05588726] | 0 participants (Actual) | Interventional | 2022-01-01 | Withdrawn (stopped due to Staff no longer available to continue enrollment and other research activities) | |||
| Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for Opioid Use and Chronic Pain Management Pilot[NCT03894501] | 30 participants (Actual) | Interventional | 2019-01-31 | Completed | |||
| Pilot Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy[NCT03022890] | 40 participants (Actual) | Interventional | 2017-04-01 | Completed | |||
| The Norwegian Addiction, Pain and Trauma Study[NCT04908410] | 1,500 participants (Anticipated) | Observational | 2021-03-23 | Recruiting | |||
| Using Difference-in-Differences to Evaluate the Effect of a Statewide Quality Improvement Program on New Persistent Opioid Use After Surgery[NCT04805229] | 30,000 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients[NCT00879996] | Phase 4 | 54 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients[NCT01559454] | Phase 4 | 19 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills[NCT03588806] | Phase 4 | 11 participants (Actual) | Interventional | 2018-05-01 | Terminated (stopped due to Study halted permanently and will not resume; participants are no longer being examined or receiving intervention.) | ||
| Chronic Pain and Opioid Dependence Assessment and Treatment[NCT00727675] | 15 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Clinical Trial of Integrated Treatment for Pain and Opioid Dependence[NCT00634803] | Phase 1/Phase 2 | 90 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| The Effects of Opioid Taper on Opioid-Induced Hyperalgesia[NCT03063905] | 15 participants (Actual) | Observational | 2017-01-31 | Terminated (stopped due to funding expired) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participants who completed 16-week assessments. (NCT03894501)
Timeframe: At 16-weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| 16-Weeks Completed | 29 |
The number of participants who complete 8-week assessments. (NCT03894501)
Timeframe: At 8-weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| 8-weeks Completed | 30 |
Anxiety was measured with the Beck Anxiety Inventory (BAI). The BAI is also a widely used, reliable, and valid scale that consists of 21 items with potential scores ranging from 0 to 63. A score of 16 or higher indicates clinically sig-nificant symptoms of anxiety. A higher score on the BAI indicates greater anxiety. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 41.05 |
| Methadone Program Behavioral Treatment as Usual | 50.83 |
The number of participants who complete baseline assessments. (NCT03894501)
Timeframe: At baseline,
| Intervention | Participants (Count of Participants) |
|---|---|
| Baselines Completed | 30 |
"Research staff asked participants if they used various drugs (i.e., heroin, cocaine, opioids, marijuana, amphetamines, inhalants, hallucinogens, benzodiazepines, zolpidem, methylphenidate, or other drugs) in the past 30 days and the number of days of use for each drug in the past 30 days. Days of illicit drug use was determined by counting the number of days each participant used drugs based on past-30 day self-reports at the16-week assessments." (NCT03894501)
Timeframe: 16-weeks
| Intervention | days (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 6.37 |
| Methadone Program Behavioral Treatment as Usual | 15.56 |
"Research staff asked participants if they used illicit opioids in the past 30 days and the number of days of use for each drug in the past 30 days. Days of illicit opioid use was determined by counting the number of days each participant used illicit opioids based on past-30 day self-reports at the 16-week assessment." (NCT03894501)
Timeframe: 16-weeks
| Intervention | days (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 2.47 |
| Methadone Program Behavioral Treatment as Usual | 5.49 |
Depression was measured with Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D scale is a widely used valid and reliable measure that consists of 20 items with potential scores ranging from 0 to 60. A score above 16 on the CES-D indicates clinically significant symptoms of depression. Higher scores on the CES-D indicates greater depression. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 34.11 |
| Methadone Program Behavioral Treatment as Usual | 42.93 |
The number of individuals consented. (NCT03894501)
Timeframe: Baseline (study enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Eligible Participants Consented | 31 |
The number of individuals screened and eligible/ineligible. (NCT03894501)
Timeframe: Baseline (study enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Individuals Screened and Ineligible. | 0 |
The mean number of sessions completed by study participants in the MORE intervention. (NCT03894501)
Timeframe: At 8-weeks (post treatment period completion).
| Intervention | number of sessions (Mean) |
|---|---|
| The Mean Number of Sessions Completed by Study Participants in the MORE Intervention. | 6.4 |
Number of participants who drop out of the study. (NCT03894501)
Timeframe: At 16 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Number of Participants Who Dropped Out of the Study. | 0 |
Research staff assessed opioid craving with a version of the Penn Alcohol Craving Scale (PACS; Flannery et al., 1999) that was adapted to assess craving to opioids at 16-weeks. Scores range from 0 to 36. Higher scores indicate greater craving. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 15.52 |
| Methadone Program Behavioral Treatment as Usual | 21.35 |
Pain was assess with the pain subscale (i.e., bodily pain severity and interference) of the RAND 36-Item Short Form Health Survey. Scores range from 0 to 100, with higher scores indicating better functioning, health, and well-being and less pain, limitations, and symptom severity or interference as compared to lower scores. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 50.76 |
| Methadone Program Behavioral Treatment as Usual | 26.65 |
Percentage of participants who completed 8-week assessments. (NCT03894501)
Timeframe: At 8-weeks.
| Intervention | percentage of 8-week assessments. (Number) |
|---|---|
| Percentage 8-weeks Completed | 100 |
Percentage of people who completed baseline assessments. (NCT03894501)
Timeframe: At baseline,
| Intervention | percentage of baseline assessments (Number) |
|---|---|
| Percentage Baselines Completed | 100 |
Percentage of participants who completed 16-week assessments. (NCT03894501)
Timeframe: At 16-weeks.
| Intervention | percentage of 16-week assessments. (Number) |
|---|---|
| Percentage of 16-weeks Completed | 96.7 |
The mean percentage of sessions completed by study participants randomized to MORE. (NCT03894501)
Timeframe: At 8-weeks (post treatment period completion).
| Intervention | percentage of sessions (Mean) |
|---|---|
| The Mean Percentage of Sessions Completed by Study Participants Randomized to MORE. | 76 |
Percentage of participants who drop out of the study. (NCT03894501)
Timeframe: At 16 weeks.
| Intervention | percentage of particpants (Number) |
|---|---|
| Percentage of Participants Who Dropped Out of the Study. | 0 |
The number of individuals who refuse participation after/during consent process. (NCT03894501)
Timeframe: Enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Individuals Who Refuse Participation After/During Consent Process. | 1 |
The number of individuals who express interest in the study. (NCT03894501)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants Who Expressed Interest in the Study | 32 |
The number of individuals who who refuse participation when offered. (NCT03894501)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Individuals Who Who Refuse Study Participation When Offered. | 2 |
This outcome assesses the number of participants who completed the treatment after 6 months. (NCT00879996)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Methadone | 13 |
| Buprenorphine/Naloxone | 13 |
We assessed functioning measured on a 0-10 point numerical rating scale (NRS)with 0 being the least amount of functioning and 10 the best amount of functioning. (NCT00879996)
Timeframe: 6 months
| Intervention | units on a 0-10 point NRS scale (Mean) |
|---|---|
| Methadone | 5.0 |
| Buprenorphine/Naloxone | 5.3 |
Pain was measured using a 0-10 point numerical rating scale (NRS) with 0 representing no pain and 10 representing worst pain possible. (NCT00879996)
Timeframe: 6 months
| Intervention | units on a 0-10 NRS scale (Mean) |
|---|---|
| Methadone | 5.4 |
| Buprenorphine/Naloxone | 5.6 |
(NCT00879996)
Timeframe: 6 months
| Intervention | number of participants (Number) |
|---|---|
| Methadone | 0 |
| Buprenorphine/Naloxone | 5 |
Pain severity will be measured using the Visual Analogue Scale (VAS) which has a range of 0-100 with 0 being no pain and 100 being worse possible pain. (NCT01559454)
Timeframe: 6 months
| Intervention | units on a VAS scale (Mean) |
|---|---|
| Methadone | 36.3 |
| Buprenorphine/Naloxone | 71.8 |
Cravings will be assessed using the Visual Analogue Scale (VAS) with 0 being no cravings and 100 being worse possible cravings (NCT01559454)
Timeframe: at 6 months
| Intervention | units on a VAS scale (Mean) |
|---|---|
| Methadone | 11.7 |
| Buprenorphine/Naloxone | 27.2 |
"Depression will be assessed using the Beck Depression Inventory, a 63 point scale with 0 being none and 63 being severe." (NCT01559454)
Timeframe: at 6 months
| Intervention | units on a BDI scale (Mean) |
|---|---|
| Methadone | 17.0 |
| Buprenorphine/Naloxone | 15.3 |
"Functioning will be assessed using the Visual Analogue Scale (VAS) with 0 being no limits and 100 being bedridden." (NCT01559454)
Timeframe: at 6 months
| Intervention | units on a VAS scale (Mean) |
|---|---|
| Methadone | 31.7 |
| Buprenorphine/Naloxone | 71.3 |
Illicit opioid use will be measured by self-report and confirmed with urine toxicology. (NCT01559454)
Timeframe: 6 months
| Intervention | participants (Number) | |
|---|---|---|
| illicit drug use at 6 months | no illicit drug use at 6 months | |
| Buprenorphine/Naloxone | 0 | 4 |
| Methadone | 0 | 6 |
Number of participants that completed the study protocol (NCT01559454)
Timeframe: 6 months
| Intervention | participants (Number) | |
|---|---|---|
| completed | did not complete | |
| Buprenorphine/Naloxone | 4 | 6 |
| Methadone | 6 | 3 |
"Pill swallowing difficulty will be measured via a 0-10 scale with 0 being no trouble at all and 10 being the greatest difficulty possible. Responses will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Baseline covers current opioid medication, and week 6 covers Xtampza ER.
| Intervention | units on a scale (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | -5.7 |
"Percent change in pain intensity (in the last 24 hours) from baseline to the end of the study averaged over the last 7 days before clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
| Intervention | percent change (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | 12.5 |
"Percent change in pain intensity (in the past 7 days) from baseline to the end of the study at clinic visit 4 (week 6). Pain Intensity is measured on a 0-10 scale, with 0 meaning no pain and 10 meaning the worst pain imaginable. As decreases in pain intensity are a sign of improvement, percent change in pain intensity is calculated as -(end of study - baseline)/baseline score." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
| Intervention | percent change (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | 9.3 |
"Opioid medication satisfaction will be measured via a 0-10 scale with 0 being not satisfied at all and 10 being completely satisfied. Responses will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study. Recorded baseline for current opioid medication and in week 6 for Xtampza ER.
| Intervention | units on a scale (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | 2.8 |
The subject's impression of the impact of the treatment on their pain and function will be measured with a 7-item scale (-3 = very much worse, -2 = much worse, -1 = minimally worse, 0 = no change, 1 = minimally improved, 2 = much improved, 3 = very much improved). Responses will be summarized as individual mean scores at clinic visit 4 (week 6). (NCT03588806)
Timeframe: Recorded in week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | 1.2 |
"The Pain Interference questions (#25-28) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Not at all and 5 being Very much. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Pain Interference T-Scores will be summarized as the change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
| Intervention | T-Score (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | -3.6 |
"The Physical Function questions (#1-4) from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 5 being Without any difficulty and 1 being Unable to do. Responses will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. Physical Function T-Scores will be summarized as change from baseline score to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
| Intervention | T-Score (Mean) |
|---|---|
| Xtampza ER (Oxycodone) Treatment | 0.7 |
"The Depression (#9-12), Anxiety (#5-8), Satisfaction with Social Roles (#21-24), and Sleep Disturbance (#17-20) questions from the PROMIS-29 Adult Profile v2.0. Questions are measured on a 5-point scale with 1 being Never and 5 being Always. Responses for each section will be summed and converted to T-Scores using the Assessment Center PROMIS Scoring Service (www.assessmentcenter.net), which rescales the raw score to a standardized T-Score with a population mean of 50 and standard deviation of 10. These T-Scores will be summarized as change from baseline scores to the end of the study at clinic visit 4 (week 6)." (NCT03588806)
Timeframe: Measured at baseline and at the end of the 6-week study
| Intervention | T-Score (Mean) | |||
|---|---|---|---|---|
| Depression | Anxiety | Satisfaction with Social Roles | Sleep Disturbance | |
| Xtampza ER (Oxycodone) Treatment | -0.4 | -1.7 | 1.1 | -3.7 |
"Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled Reduced illicit opioid use and the timeframe was listed as 16 weeks." (NCT00634803)
Timeframe: 3 Months
| Intervention | opioid negative urine tests (Mean) | |||
|---|---|---|---|---|
| Intake/Induction | Month 1 | Month 2 | Month 3 | |
| CBT for POD | 0.67 | 2.67 | 2.96 | 2.80 |
| Educational Counseling for POD | 0.67 | 2.80 | 3.30 | 3.25 |
| Physician Management | 0.55 | 2.48 | 2.56 | 2.04 |
Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe. (NCT00634803)
Timeframe: 3 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Intake/Induction | Month 1 | Month 2 | Month 3 | |
| CBT for POD | 5.43 | 4.75 | 4.79 | 4.41 |
| Educational Counseling for POD | 5.92 | 5.02 | 4.98 | 4.62 |
| Physician Management | 5.28 | 4.53 | 4.72 | 4.84 |
Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference. (NCT00634803)
Timeframe: 3 Months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Intake/Induction | Month 1 | Month 2 | Month 3 | |
| CBT for POD | 5.75 | 4.15 | 4.08 | 3.22 |
| Educational Counseling for POD | 5.48 | 3.74 | 3.61 | 3.23 |
| Physician Management | 5.01 | 3.32 | 3.45 | 3.87 |
18 reviews available for methadone and Pain, Chronic
| Article | Year |
|---|---|
Systematic review on the clinical management of chronic pain and comorbid opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; O | 2023 |
Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opiate Substitution Treat | 2023 |
Intravenous Methadone for Perioperative and Chronic Cancer Pain: A Review of the Literature.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Chronic Pain; Humans; Methadone; Neoplasms; Pain, Posto | 2023 |
The effect of methadone on the hypothalamic pituitary gonadal axis and sexual function: A systematic review.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Female; Gonadal Disorders; Humans; Hypothalamo-Hypophysea | 2020 |
Levorphanol versus methadone use: safety considerations.
Topics: Analgesics, Opioid; Central Nervous System; Chronic Pain; Dose-Response Relationship, Drug; Humans; | 2020 |
Methadone for Pain Management: A Pharmacotherapeutic Review.
Topics: Analgesics, Opioid; Cancer Pain; Chronic Pain; Humans; Methadone; Pain Management; Prospective Studi | 2020 |
Acute Pain Management of Chronic Pain Patients in Ambulatory Surgery Centers.
Topics: Acute Pain; Analgesics, Opioid; Anesthesia, Conduction; Buprenorphine, Naloxone Drug Combination; Ch | 2021 |
Treatment of Chronic Pain With Various Buprenorphine Formulations: A Systematic Review of Clinical Studies.
Topics: Administration, Buccal; Administration, Cutaneous; Administration, Sublingual; Analgesics, Opioid; B | 2018 |
Prevention of Opioid Overdose.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Drug Overdose; Humans; Methadone; Naloxone; Narcoti | 2019 |
Comprehensive Perioperative Management Considerations in Patients Taking Methadone.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opioid-Related Disorders; Pain M | 2019 |
Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline.
Topics: Arrhythmias, Cardiac; Chronic Pain; Drug Overdose; Humans; Methadone; Opioid-Related Disorders; Prac | 2014 |
Cardiac Effects of Opioid Therapy.
Topics: Analgesics, Opioid; Chronic Pain; Heart; Humans; Methadone; Risk | 2015 |
Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies.
Topics: Analgesics, Opioid; Benzodiazepines; Chronic Pain; Drug Overdose; Humans; Methadone; Sleep Wake Diso | 2015 |
Pain and Opioid Addiction: A Systematic Review and Evaluation of Pain Measurement in Patients with Opioid Dependence on Methadone Maintenance Treatment.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2016 |
A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2016 |
Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhi | 2011 |
Methadone for chronic non-cancer pain in adults.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Humans; Methadone; Neuralgia; Neuralgia, Postherpetic; Rand | 2012 |
Chronic and acute pain and pain management for patients in methadone maintenance treatment.
Topics: Acute Pain; Analgesics; Catastrophization; Chronic Pain; Drug Tolerance; Female; Humans; Methadone; | 2013 |
11 trials available for methadone and Pain, Chronic
62 other studies available for methadone and Pain, Chronic
| Article | Year |
|---|---|
A cohort study examining the relationship among housing status, patient characteristics, and retention among individuals enrolled in low-barrier-to-treatment-access methadone maintenance treatment.
Topics: Chronic Pain; Cohort Studies; Female; Housing; Humans; Methadone; Opiate Substitution Treatment; Ret | 2022 |
Microinduction to Buprenorphine from Methadone for Chronic Pain: Outpatient Protocol with Case Examples.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opioid-Related Disorders; Outpat | 2022 |
Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Death; G Protein-Coupled Inwardly-Rectifying Potassium Chan | 2022 |
Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids.
Topics: Adolescent; Adult; Analgesics, Opioid; Australia; Chronic Pain; Drug Overdose; Drug Prescriptions; F | 2019 |
Associations Among Sleep Disturbance, Pain Catastrophizing, and Pain Intensity for Methadone-maintained Patients With Opioid Use Disorder and Chronic Pain.
Topics: Adult; Catastrophization; Chronic Pain; Cross-Sectional Studies; Female; Humans; Male; Methadone; Mi | 2020 |
Methadone and Chronic Pain: Reply.
Topics: Analgesics; Analgesics, Opioid; Cardiac Surgical Procedures; Chronic Pain; Humans; Methadone; Pain, | 2020 |
Methadone and Chronic Pain: Comment.
Topics: Analgesics; Analgesics, Opioid; Cardiac Surgical Procedures; Chronic Pain; Humans; Methadone; Pain, | 2020 |
Post-traumatic stress disorder due to sexual abuse and its relation to pain sensitivity among patients in methadone maintenance treatment.
Topics: Chronic Pain; Humans; Methadone; Pain Threshold; Sex Offenses; Stress Disorders, Post-Traumatic | 2021 |
Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Humans; Male; Methadone; Opiate Subs | 2021 |
Some controversies related to questionable clinical uses of methadone for chronic non-cancer pain and in palliative care.
Topics: Analgesics, Opioid; Cancer Pain; Chronic Pain; Humans; Methadone; Palliative Care | 2021 |
Chronic Pain Among Patients With an Opioid Use Disorder.
Topics: Adolescent; Adult; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Female; Humans; Male; Metha | 2021 |
Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Drug Monitoring; Fe | 2021 |
Very-Low-Dose Methadone To Treat Refractory Neuropathic Pain in Children with Cancer.
Topics: Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Child; Child, Preschool; Chronic Pain; Cyclohex | 2017 |
Opioid tapering in patients with prescription opioid use disorder: A retrospective study.
Topics: Analgesics, Opioid; Chronic Pain; Drug Prescriptions; Female; Humans; Male; Methadone; Middle Aged; | 2017 |
Methadone-Associated Hypoglycemia in Chronic Renal Failure Masquerading as an Insulinoma.
Topics: Adult; Analgesics, Opioid; Back Pain; Chronic Pain; Diagnosis, Differential; Female; Humans; Hypogly | 2018 |
Patterns of regional variation of opioid prescribing in primary care in England: a retrospective observational study.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Crime; Databases, Factual; Education; Employment; E | 2018 |
Training addiction counselors to deliver a brief psychoeducational intervention for chronic pain among patients in opioid agonist treatment: A pilot investigation.
Topics: Analgesics, Opioid; Chronic Pain; Counselors; Female; Health Knowledge, Attitudes, Practice; Humans; | 2018 |
Management of severe chronic pain with methadone in pediatric patients with sickle cell disease.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Child; Chronic Pain; Cohort Studies; Female; Hu | 2018 |
Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Hospitalization; Humans; Immunosupp | 2019 |
Substance misuse in patients who have comorbid chronic pain in a clinical population receiving methadone maintenance therapy for the treatment of opioid dependence.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Chronic Pain; Female; Humans; Male; Methadone; Opiate Su | 2018 |
Profiles of visuospatial memory dysfunction in opioid-exposed and dependent populations.
Topics: Adult; Agnosia; Analgesics, Opioid; Chronic Pain; Codeine; Female; Heroin Dependence; Humans; Male; | 2019 |
Association Between Socio-Demographic and Health Functioning Variables Among Patients with Opioid Use Disorder Introduced by Prescription: A Prospective Cohort Study.
Topics: Adult; Aged; Analgesics, Opioid; Canada; Chronic Pain; Female; Humans; Male; Methadone; Middle Aged; | 2018 |
Should Physicians Recommend Replacing Opioids With Cannabis?
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Evidence-Based Medicine; Government Regulation; Hum | 2019 |
Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.
Topics: Adult; Algorithms; Analgesics; Child; Chronic Pain; Clinical Decision-Making; Humans; Ketamine; Medi | 2019 |
Psycho-physiological response to pain among individuals with comorbid pain and opioid use disorder: Implications for patients with prolonged abstinence.
Topics: Adaptation, Psychological; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Humans; M | 2019 |
Comparison of psychiatric comorbidity in treatment-seeking, opioid-dependent patients with versus without chronic pain.
Topics: Adult; Analgesics, Opioid; Anti-Anxiety Agents; Antimanic Agents; Chronic Pain; Cohort Studies; Como | 2020 |
A review of methadone deaths between 2001 and 2005 in Victoria, Australia.
Topics: Adolescent; Adult; Australia; Cause of Death; Chronic Pain; Dose-Response Relationship, Drug; Female | 2013 |
Management of chronic neuropathic pain of different causes with the combination of oral methadone along with ketamine: A report of 18 cases.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Chronic Pain; Drug Combinations; Female; Humans; Ke | 2013 |
Categorising methadone: Addiction and analgesia.
Topics: Analgesics, Opioid; Behavior, Addictive; Chronic Pain; Drug Users; Humans; Methadone; Opiate Substit | 2013 |
Psychopathology and pain correlates of dispositional optimism in methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Attitude; Chronic Pain; Depressive Disorder; Female; Health Status; Human | 2012 |
Eight principles for safer opioid prescribing.
Topics: Acute Pain; Analgesics, Opioid; Asthma; Benzodiazepines; Chronic Pain; Delayed-Action Preparations; | 2013 |
Coexisting addiction and pain in people receiving methadone for addiction.
Topics: Adult; Chronic Pain; Female; Humans; Male; Methadone; Middle Aged; Narration; Opioid-Related Disorde | 2014 |
Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives.
Topics: Analgesics, Opioid; Child; Chronic Pain; Data Collection; Deglutition Disorders; Fentanyl; Humans; M | 2014 |
Urinary diazepam metabolite distribution in a chronic pain population.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Chronic Pain; Cytochrome P-450 | 2014 |
Achievement of take-home dose privileges is associated with better-perceived sleep and with cognitive status among methadone maintenance treatment patients.
Topics: Chronic Pain; Cognition; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Neuropsychological | 2014 |
Severity and interference of chronic pain in methadone-maintained outpatients.
Topics: Adult; Age Factors; Baltimore; Benzodiazepines; Chronic Pain; Cocaine; Cocaine-Related Disorders; Co | 2014 |
Prevalence of heroin markers in urine for pain management patients.
Topics: Analgesics, Opioid; Biomarkers; Buprenorphine; Chromatography, Liquid; Chronic Pain; Codeine; Heroin | 2014 |
Methadone and prescription drug overdose.
Topics: Analgesics, Opioid; Chronic Pain; Drug Overdose; Drug Prescriptions; Formularies as Topic; Humans; M | 2014 |
The QTc effect of low-dose methadone for chronic pain: a prospective pilot study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Cohort Studies; Dose-Response Rela | 2015 |
Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance.
Topics: Amphetamine; Analgesics, Opioid; Chronic Pain; Cocaine; Female; Humans; Longitudinal Studies; Male; | 2015 |
Promethazine use among chronic pain patients.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Histamine H1 Antagonists; Humans; | 2015 |
Associations between chronic non-cancer pain and medication assisted treatment outcomes for opiate addiction.
Topics: Adult; Anxiety; Chronic Pain; Comorbidity; Depression; Female; Humans; Kentucky; Male; Methadone; Op | 2015 |
Tapering and discontinuation of methadone for chronic pain.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Male; Methadone; Middle Aged; Pain Management; Pain, Posto | 2015 |
Pain Among High-Risk Patients on Methadone Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Canada; Chronic Pain; Cohort Studies; Dose-Response Relationship, Drug; F | 2015 |
Ten Years of Abstinence in Former Opiate Addicts: Medication-Free Non-Patients Compared to Methadone Maintenance Patients.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Chronic Pain; Cognition; Comorbidity; Female; Humans | 2015 |
Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.
Topics: Adaptation, Psychological; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Humans; M | 2015 |
Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain.
Topics: Adult; Aged; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Chronic Pain; Drug Overdose; Fe | 2016 |
Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Cohort Studies; Comorbidity; Cross-Sectional Studies; | 2016 |
Physical activity, psychiatric distress, and interest in exercise group participation among individuals seeking methadone maintenance treatment with and without chronic pain.
Topics: Adult; Chronic Pain; Exercise; Female; Humans; Male; Mental Disorders; Methadone; Middle Aged; Opiat | 2016 |
Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain.
Topics: Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Cardiovascular Diseases; Cause of Death; | 2016 |
Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Craving; Cross-Sectional Studies; Depression | 2016 |
Predictive Value of Positive Drug Screening Results in an Urban Outpatient Population.
Topics: Amphetamines; Analgesics, Opioid; Barbiturates; Benzodiazepines; Cannabinoids; Chronic Pain; Cocaine | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Methadone Inpatient and Discharge Prescribing Patterns for Pain at an Academic Health System.
Topics: Adult; Chronic Pain; Female; Humans; Inpatients; Male; Medical Audit; Methadone; Middle Aged; Opioid | 2017 |
Drug Counselor Responses to Patients' Pain Reports: A Qualitative Investigation of Barriers and Facilitators to Treating Patients with Chronic Pain in Methadone Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Female; Health Knowledge, Attitudes, Practice; Humans; Male | 2017 |
Patient education and self-advocacy: queries and responses on pain management.
Topics: Caffeine; Chronic Pain; Headache; Humans; Methadone; Pain Management; Sleep Apnea Syndromes | 2008 |
Individual patient assessment of methadone-induced QT prolongation with digital holter recording.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Dose-Response Relationship, Drug; Electrocardiography, Ambu | 2012 |
Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients.
Topics: Analgesics, Opioid; Chromatography, High Pressure Liquid; Chronic Pain; Humans; Hydrogen-Ion Concent | 2012 |
Cross-reactivity of tapentadol specimens with DRI methadone enzyme immunoassay.
Topics: Analgesics; Chromatography, High Pressure Liquid; Chronic Pain; Cross Reactions; False Positive Reac | 2012 |
Unpredictable absorption of oral opioid medications in a quadriplegic patient with chronic enterocutaneous fistulas.
Topics: Administration, Oral; Analgesics, Opioid; Benzodiazepines; Biological Availability; Chronic Disease; | 2012 |
Methadone in the chronic pain patient with a substance use disorder.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Methadone; Opioid-Related Disorders; Substance-Related Dis | 2012 |
Adductor canal nerve catheter for post-operative management of medial ankle pain following ankle fusion.
Topics: Adult; Analgesics, Opioid; Ankle; Catheterization, Peripheral; Catheters; Chronic Pain; Female; Huma | 2013 |